IL124909A - The process involving ultrasound and sodium hypochlorite in the preparation of a fraction of hyaluronic acid with a low polydispersity index - Google Patents

The process involving ultrasound and sodium hypochlorite in the preparation of a fraction of hyaluronic acid with a low polydispersity index

Info

Publication number: IL124909A
Authority: IL; Israel
Prior art keywords: hyaluronic acid; molecular weight; process according; weight ranging; average molecular
Prior art date: 1995-12-20

Application number

IL12490996A

Other languages

English (en)

Hebrew (he)

Other versions

IL124909A0 (en

Original Assignee

Fidia Advanced Biopolymers Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-20

Filing date

1996-12-19

Publication date

2002-09-12

1996-12-19 Application filed by Fidia Advanced Biopolymers Srl filed Critical Fidia Advanced Biopolymers Srl

1996-12-19 Priority to IL14123096A priority Critical patent/IL141230A/en

1999-01-26 Publication of IL124909A0 publication Critical patent/IL124909A0/xx

2002-09-12 Publication of IL124909A publication Critical patent/IL124909A/en

Links

KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 92
229920002674 hyaluronan Polymers 0.000 title claims abstract description 86
229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 86
238000002604 ultrasonography Methods 0.000 title claims abstract description 31
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 title claims abstract description 21
239000005708 Sodium hypochlorite Substances 0.000 title claims abstract description 20
238000000034 method Methods 0.000 title claims description 56
230000008569 process Effects 0.000 title claims description 34
239000000061 acid fraction Substances 0.000 title claims description 22
150000003839 salts Chemical class 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 6
230000033115 angiogenesis Effects 0.000 claims abstract description 4
230000011164 ossification Effects 0.000 claims abstract description 4
230000017423 tissue regeneration Effects 0.000 claims abstract description 4
239000000243 solution Substances 0.000 claims description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
239000011780 sodium chloride Substances 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 4
241000561734 Celosia cristata Species 0.000 claims description 3
210000001520 comb Anatomy 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 2
238000000855 fermentation Methods 0.000 claims description 2
230000004151 fermentation Effects 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims description 2
238000003786 synthesis reaction Methods 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims 1
238000006731 degradation reaction Methods 0.000 description 14
230000015556 catabolic process Effects 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 10
238000004458 analytical method Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
230000009471 action Effects 0.000 description 7
WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical class Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 3
GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 description 3
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 3
238000001914 filtration Methods 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
108010003272 Hyaluronate lyase Proteins 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 2
238000000053 physical method Methods 0.000 description 2
238000009210 therapy by ultrasound Methods 0.000 description 2
NJNFCDQQEIAOIF-UHFFFAOYSA-N 2-(3,4-dimethoxy-2-methylsulfanylphenyl)ethanamine Chemical compound COC1=CC=C(CCN)C(SC)=C1OC NJNFCDQQEIAOIF-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
229910019093 NaOCl Inorganic materials 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000012691 depolymerization reaction Methods 0.000 description 1
125000000600 disaccharide group Chemical group 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000007620 mathematical function Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000000569 multi-angle light scattering Methods 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Materials Engineering (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL12490996A 1995-12-20 1996-12-19 The process involving ultrasound and sodium hypochlorite in the preparation of a fraction of hyaluronic acid with a low polydispersity index IL124909A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL14123096A IL141230A (en)	1995-12-20	1996-12-19	Hyaluronic acid derivatives obtained from hyaluronic acid fraction having a low polydispersion index and pharmaceutical compositions and healthcare products containing them

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT95PD000244A IT1282219B1 (it)	1995-12-20	1995-12-20	Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa
PCT/EP1996/005701 WO1997022629A1 (en)	1995-12-20	1996-12-19	A process for preparing a hyaluronic acid fraction having a low polydispersion index

Publications (2)

Publication Number	Publication Date
IL124909A0 IL124909A0 (en)	1999-01-26
IL124909A true IL124909A (en)	2002-09-12

Family

ID=11391198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12490996A IL124909A (en)	1995-12-20	1996-12-19	The process involving ultrasound and sodium hypochlorite in the preparation of a fraction of hyaluronic acid with a low polydispersity index

Country Status (14)

Country	Link
US (2)	US6020484A (it)
EP (1)	EP0868437B1 (it)
JP (1)	JP4094059B2 (it)
AT (1)	ATE184024T1 (it)
AU (1)	AU703332B2 (it)
CZ (1)	CZ291394B6 (it)
DE (1)	DE69604087T2 (it)
DK (1)	DK0868437T3 (it)
ES (1)	ES2139402T3 (it)
GR (1)	GR3031973T3 (it)
HU (1)	HU226949B1 (it)
IL (1)	IL124909A (it)
IT (1)	IT1282219B1 (it)
WO (1)	WO1997022629A1 (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1282219B1 (it) *	1995-12-20	1998-03-16	Fidia Advanced Biopolymers Srl	Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa
IT1291452B1 (it)	1997-04-14	1999-01-11	Fidia Advanced Biopolymers Srl	Rivestimento a base di acido ialuronico e suoi derivati per la protezione di parti elettroniche da agenti esterni
US20020172712A1 (en) *	2001-03-19	2002-11-21	Alan Drizen	Antiemetic, anti-motion sustained release drug delivery system
WO2003084571A1 (en) *	2002-04-08	2003-10-16	Denki Kagaku Kogyo Kabushiki Kaisha	Therapeutic composition for bone infectious disease
WO2003094937A1 (en) *	2002-05-09	2003-11-20	Medigenes	A pharmaceutical composition for treatment of wounds containing blood plasma or serum
TW200638946A (en) *	2002-05-17	2006-11-16	Wyeth Corp	Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
WO2004004671A1 (en) *	2002-07-02	2004-01-15	Procyte Corporation	Compositions containing peptide copper complexes and soft tissue fillers
US20060183709A1 (en) *	2005-02-15	2006-08-17	Ahmad Alkayali	Preparation of low molecular weight hyaluronic acid as a food supplement
JP4576583B2 (ja) *	2005-03-22	2010-11-10	キユーピー株式会社	ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US7323184B2 (en) *	2005-08-22	2008-01-29	Healagenics, Inc.	Compositions and methods for the treatment of wounds and the reduction of scar formation
JP5289936B2 (ja) *	2006-02-24	2013-09-11	キユーピー株式会社	新規な低分子ヒアルロン酸および／またはその塩、ならびにこれを用いた化粧料、医薬組成物および食品組成物
WO2008000260A1 (en) *	2006-06-28	2008-01-03	Novozymes Biopolymer A/S	Compositions with several hyaluronic acid fractions for cosmetic and medical uses
WO2008003321A2 (en) *	2006-07-07	2008-01-10	Novozymes Biopolymer A/S	Compositions with several hyaluronic acid fractions for cosmetic use
US8202986B2 (en)	2006-08-04	2012-06-19	Novozymes Biopolymer AIS	Branched hyaluronic acid and method of manufacture
US8529951B1 (en)	2007-02-21	2013-09-10	Anand Ramamurthi	Elastogenic cues and methods for using same
ES2622834T3 (es)	2007-11-13	2017-07-07	Bio-Technology General (Israel) Ltd.	Procedimiento de esterilización por filtración en estado diluido para biopolímeros viscoelásticos
US20130209531A1 (en) *	2010-06-08	2013-08-15	University Of Utah Research Foundation	Applications of partially and fully sulfated hyaluronan
ES2893838T3 (es) *	2016-03-02	2022-02-10	Merz Pharma Gmbh & Co Kgaa	Composición que comprende toxina botulínica
CN113512134B (zh) *	2021-07-30	2022-05-20	梅晔生物医药股份有限公司	一种全分子量分布的透明质酸钠及其制备方法和应用
JP7503278B1 (ja)	2024-02-09	2024-06-20	株式会社ブルー・スターR&D	低分子ヒアルロン酸の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5166331A (en) *	1983-10-10	1992-11-24	Fidia, S.P.A.	Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IN163192B (it) *	1983-10-11	1988-08-20	Fidia Spa
US4851521A (en) *	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
GB8713747D0 (en) *	1987-06-12	1987-07-15	Unilever Plc	Skin treatment composition
IT1219587B (it) *	1988-05-13	1990-05-18	Fidia Farmaceutici	Polisaccaridi carbossiilici autoreticolati
JPH0675512B2 (ja) *	1989-03-20	1994-09-28	株式会社紀文食品	低重合度ヒアルロン酸アルカリ塩の製造方法
IT1247175B (it) *	1991-04-19	1994-12-12	Fidia Spa	Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico.
IT1260148B (it) *	1992-04-17	1996-03-28	Fidia Spa	Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
IT1268954B1 (it) *	1994-03-11	1997-03-18	Fidia Advanced Biopolymers Srl	Processo per la preparazione di acido ialuronico mediante sintesienzimatica e relative composizioni farmaceutiche
ITPD940054A1 (it) *	1994-03-23	1995-09-23	Fidia Advanced Biopolymers Srl	Polisaccaridi solfatati
IT1282219B1 (it) *	1995-12-20	1998-03-16	Fidia Advanced Biopolymers Srl	Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa

1995
- 1995-12-20 IT IT95PD000244A patent/IT1282219B1/it active IP Right Grant
1996
- 1996-12-19 AT AT96944007T patent/ATE184024T1/de active
- 1996-12-19 JP JP52251197A patent/JP4094059B2/ja not_active Expired - Fee Related
- 1996-12-19 EP EP96944007A patent/EP0868437B1/en not_active Expired - Lifetime
- 1996-12-19 US US09/096,646 patent/US6020484A/en not_active Expired - Lifetime
- 1996-12-19 WO PCT/EP1996/005701 patent/WO1997022629A1/en not_active Ceased
- 1996-12-19 IL IL12490996A patent/IL124909A/en not_active IP Right Cessation
- 1996-12-19 DK DK96944007T patent/DK0868437T3/da active
- 1996-12-19 CZ CZ19981889A patent/CZ291394B6/cs not_active IP Right Cessation
- 1996-12-19 DE DE69604087T patent/DE69604087T2/de not_active Expired - Lifetime
- 1996-12-19 HU HU9903666A patent/HU226949B1/hu not_active IP Right Cessation
- 1996-12-19 ES ES96944007T patent/ES2139402T3/es not_active Expired - Lifetime
- 1996-12-19 AU AU13749/97A patent/AU703332B2/en not_active Ceased
1999
- 1999-10-26 US US09/426,536 patent/US6232303B1/en not_active Expired - Lifetime
- 1999-11-29 GR GR990403066T patent/GR3031973T3/el unknown

Also Published As

Publication number	Publication date
WO1997022629A1 (en)	1997-06-26
EP0868437A1 (en)	1998-10-07
DE69604087D1 (de)	1999-10-07
HUP9903666A3 (en)	2001-03-28
ES2139402T3 (es)	2000-02-01
GR3031973T3 (en)	2000-03-31
DK0868437T3 (da)	2000-03-13
US6020484A (en)	2000-02-01
EP0868437B1 (en)	1999-09-01
JP2000502141A (ja)	2000-02-22
AU1374997A (en)	1997-07-14
US6232303B1 (en)	2001-05-15
AU703332B2 (en)	1999-03-25
ATE184024T1 (de)	1999-09-15
ITPD950244A0 (it)	1995-12-20
ITPD950244A1 (it)	1997-06-20
JP4094059B2 (ja)	2008-06-04
DE69604087T2 (de)	2000-02-24
IT1282219B1 (it)	1998-03-16
CZ188998A3 (cs)	1998-09-16
HU226949B1 (en)	2010-03-29
HUP9903666A2 (hu)	2000-03-28
IL124909A0 (en)	1999-01-26
CZ291394B6 (cs)	2003-02-12

Legal Events

Date	Code	Title
2003-02-12	FF	Patent granted
2003-03-12	KB	Patent renewed
2003-07-31	HP	Change in proprietorship
2007-02-12	KB	Patent renewed
2010-12-30	KB	Patent renewed
2015-07-30	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US6020484A (en)	2000-02-01	Process for preparing a hyaluronic acid fraction having a low polydispersion index
EP1144459B2 (en)	2011-02-23	Cross-linked hyaluronic acids and medical uses thereof
AU738788B2 (en)	2001-09-27	N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation
Sudha et al.	2014	Beneficial effects of hyaluronic acid
CA2361981C (en)	2008-06-10	Process for the production of multiple cross-linked hyaluronic acid derivatives
DK173818B1 (da)	2001-11-19	Heparinderivat
EP2772273A2 (en)	2014-09-03	Viscoelastic gels as novel fillers
JP2004507586A (ja)	2004-03-11	過カルボン酸エステル化された多糖類、及びそれらの作製方法
Káčerová et al.	2024	Chitosan/dialdehyde cellulose hydrogels with covalently anchored polypyrrole: Novel conductive, antibacterial, antioxidant, immunomodulatory, and anti-inflammatory materials
JP2009545637A (ja)	2009-12-24	分岐ヒアルロン酸及びその製造方法
KR20100092494A (ko)	2010-08-20	산성 다당체의 부티르산-포름산 에스테르 혼합물, 및 그의 제조 및 피부 화장료로서의 용도
CA2240682C (en)	2006-02-14	A process for preparing a hyaluronic acid fraction having a low polydispersion index
IL141230A (en)	2004-02-08	Hyaluronic acid derivatives obtained from hyaluronic acid fraction having a low polydispersion index and pharmaceutical compositions and healthcare products containing them
EP3922268B1 (en)	2023-02-22	New derivatives obtained from hyaluronic acid and carnosine
JP2024509534A (ja)	2024-03-04	ポリマーをベースとする植込み型又は注入型生成物及びそれらの調製方法
Esquivel-Lozano et al.	2026	Stimulus-responsive comb-like hydrogels of poly (vinyl alcohol) grafted with methacrylamide and acrylic acid by gamma radiation
CN114516923A (zh)	2022-05-20	一种双键官能化修饰的透明质酸(钠)及其合成方法和应用
MXPA01004712A (en)	2002-06-05	Cross-linked hyaluronic acids and medical uses thereof
HK1196787B (en)	2017-01-20	Viscoelastic gels as novel fillers